Catalyst Wire Dossier Catalyst Wire Dossier

Beloranib (ZGN-440)

Beloranib · Zafgen, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Beloranib (ZGN-440), covering 2017-01-26 to 2017-01-26. Get the full timeline:

Most recent: Clinical Trial Update: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome [Phase 3]

See pricing